Clinical trial
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor…
NCT00016068 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00016068 |
|---|---|
| Title | Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation |
| Official title | A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infection |
| Intervention type | Drug |
| Interventions | ganciclovir, valganciclovir |
| Enrollment | 184 |
| Start date | Jan 1, 2001 |
| Completion | Sep 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | May 17, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: